4DMedical Ltd.ASX: 4DX

Investor Presentation - FDA Submission for CTVQ

· Issued by 4DMedical Ltd.

Filed with ASX · · 34 pages · English

Summary by 6ix AI

It highlights the completion of clinical evaluations and the strong correlation of CT:VQ results with traditional imaging techniques. The document emphasizes the importance of regulatory clearance for commercial use and the expected impact on lung health diagnostics.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

4DMedical Ltd. on 6ix

In the deck

Story so far

Earlier from 4DMedical

Later from 4DMedical

All 4DMedical news releases